Mon, May 2, 8:45 AM
- The achievement of certain regulatory and sales milestones triggers the payment of two undisclosed milestone payments to Kamada (NASDAQ:KMDA) from strategic partners Chiesi Farmaceutici S.p.A. and Baxalta (NYSE:BXLT).
- The milestone from Chiesi was based on the filing of a Marketing Authorization Application (MAA) in Europe for inhaled alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency.
- The Baxalta payment was based on achieving a sales milestone related to Glassia, Kamada's intravenous AAT treatment. Baxalta is the exclusive distributor for all indications in the U.S., Canada, Australia and New Zealand.
- Kamada will record the payments as deferred revenue and will recognize them during the terms of the agreements. The company expects Glassia revenue to hit $100M next year.
- Shares are up 9% premarket on light volume.
Jan. 5, 2015, 8:43 AM
- Thinly-traded nano cap Kamada (NASDAQ:KMDA) is up 13% premarket on increased volume. No specific news accounts for the move. Several weeks ago, the company announced positive interim results from a Phase 1/2 trial evaluating its human Apha-1 Antitrypsin for the treatment of graft-versus-host disease.
Nov. 12, 2014, 8:47 AM
Sep. 4, 2014, 8:13 AM
May 16, 2014, 8:02 AM
Sep. 12, 2013, 10:43 AM
- Kamada (KMDA +1.5%) rises as investors anticipate results from a European trial of an inhaled version of Antitrypsin, an AAT treatment. See profile on KMDA's website.
- The Phase II/III study is scheduled to be completed by year-end.
- Here's Jefferies Raj Denhoy (as quoted by Bloomberg): “If the trial is successful, and I think there is a pretty good chance for it to be a success, Kamada will have the only inhalable version of the drug on the market."
- Jefferies estimate: $800M/year globally.
Jun. 25, 2013, 12:28 PM
Another biotech IPO coming out of its quiet period today is Kamada (KMDA +3.3%), being initiated by a number of firms with an overall bullish outlook: Jefferies kicks off coverage with a Buy, and Oppenheimer with an Outperform. Both say the real story here lies in its development of an inhalable version of alpha 1 antitrypsin. Data on the European study will be available in January and should it prove successful, it will likely be transformative for the company. Separately, Morgan Stanley starts the shares off with an Equal-weight rating.| Jun. 25, 2013, 12:28 PM
Jun. 5, 2013, 12:56 PM